menu
    • menu
    [{"orgOrder":0,"company":"Miltenyi Biotec","sponsor":"Miltenyi Biotec","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"CAR20.19.22 Cell","moa":"CD20\/CD19\/CD22","graph1":"Oncology","graph2":"Phase I","graph3":"Miltenyi Biotec","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Miltenyi Biotec \/ Miltenyi Biotec","highestDevelopmentStatusID":"6","companyTruncated":"Miltenyi Biotec \/ Miltenyi Biotec"},{"orgOrder":0,"company":"Miltenyi Biotec","sponsor":"Miltenyi Biotec","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2014","type":"Inapplicable","leadProduct":"CMV-Specific CTL","moa":"CMV","graph1":"Oncology","graph2":"Phase II","graph3":"Miltenyi Biotec","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Miltenyi Biotec \/ Miltenyi Biotec","highestDevelopmentStatusID":"8","companyTruncated":"Miltenyi Biotec \/ Miltenyi Biotec"},{"orgOrder":0,"company":"Miltenyi Biotec","sponsor":"Miltenyi Biotec","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BRAZIL","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"DNA","graph1":"Oncology","graph2":"Phase I","graph3":"Miltenyi Biotec","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Miltenyi Biotec \/ Miltenyi Biotec","highestDevelopmentStatusID":"6","companyTruncated":"Miltenyi Biotec \/ Miltenyi Biotec"},{"orgOrder":0,"company":"Miltenyi Biotec","sponsor":"Miltenyi Biotec","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Cell & Gene Therapy","year":"2011","type":"Inapplicable","leadProduct":"Autologous CD133+ stem cell","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Miltenyi Biotec","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Miltenyi Biotec \/ Miltenyi Biotec","highestDevelopmentStatusID":"8","companyTruncated":"Miltenyi Biotec \/ Miltenyi Biotec"},{"orgOrder":0,"company":"Miltenyi Biotec","sponsor":"Cell BioEngines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell & Gene Therapy","year":"2023","type":"Agreement","leadProduct":"CBE-101","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Miltenyi Biotec","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Miltenyi Biotec \/ Cell BioEngines","highestDevelopmentStatusID":"5","companyTruncated":"Miltenyi Biotec \/ Cell BioEngines"},{"orgOrder":0,"company":"Miltenyi Biotec","sponsor":"Syena","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell & Gene Therapy","year":"2023","type":"Licensing Agreement","leadProduct":"SY-001","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Miltenyi Biotec","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Miltenyi Biotec \/ Syena","highestDevelopmentStatusID":"5","companyTruncated":"Miltenyi Biotec \/ Syena"},{"orgOrder":0,"company":"Miltenyi Biotec","sponsor":"Miltenyi Biotec","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"TCR\u03b1\u03b2+\/CD45RA","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Miltenyi Biotec","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Miltenyi Biotec \/ Miltenyi Biotec","highestDevelopmentStatusID":"1","companyTruncated":"Miltenyi Biotec \/ Miltenyi Biotec"},{"orgOrder":0,"company":"Miltenyi Biotec","sponsor":"Iovance Biotherapeutics | UPMC Hillman Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Autologous Pleural Infiltrating T-Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Miltenyi Biotec","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Catheter","sponsorNew":"Miltenyi Biotec \/ Iovance Biotherapeutics | UPMC Hillman Cancer Center","highestDevelopmentStatusID":"6","companyTruncated":"Miltenyi Biotec \/ Iovance Biotherapeutics | UPMC Hillman Cancer Center"},{"orgOrder":0,"company":"Miltenyi Biotec","sponsor":"Verismo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell & Gene Therapy","year":"2025","type":"Collaboration","leadProduct":"SynKIR-110","moa":"MSLN","graph1":"Oncology","graph2":"Phase I","graph3":"Miltenyi Biotec","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Miltenyi Biotec \/ Verismo Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Miltenyi Biotec \/ Verismo Therapeutics"},{"orgOrder":0,"company":"Miltenyi Biotec","sponsor":"John Lister","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"CAR-T Cell","moa":"Chimeric antigen receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Miltenyi Biotec","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Miltenyi Biotec \/ John Lister","highestDevelopmentStatusID":"8","companyTruncated":"Miltenyi Biotec \/ John Lister"},{"orgOrder":0,"company":"Miltenyi Biotec","sponsor":"Joanne Kurtzberg, MD","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"CliniMACS CD34 Reagent System","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Miltenyi Biotec","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Miltenyi Biotec \/ Joanne Kurtzberg, MD","highestDevelopmentStatusID":"1","companyTruncated":"Miltenyi Biotec \/ Joanne Kurtzberg, MD"},{"orgOrder":0,"company":"Miltenyi Biotec","sponsor":"Yae-Jean Kim","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Ifn-Gamma Positive-Selected T-Cell","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Miltenyi Biotec","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Miltenyi Biotec \/ Yae-Jean Kim","highestDevelopmentStatusID":"7","companyTruncated":"Miltenyi Biotec \/ Yae-Jean Kim"}]

    Find Clinical Drug Pipeline Developments & Deals by Miltenyi Biotec

    Menu

    Miltenyi Biotec

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Miltenyi Biotec

                            Germany arrow
                            CPhI India
                            Not Confirmed

                            Miltenyi Biotec

                            Germany arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Autologous Pleural Infiltrating T-Cell

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Iovance Biotherapeutics | UPMC Hillman Cancer Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Fast TILs to Treat Metastatic Cancer Patients With Pleural Disease

                            Details : Autologous Pleural Infiltrating T-Cell is a Cell & Gene Therapy drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Pleural Effusion, Malignant.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            September 25, 2025

                            Lead Product(s) : Autologous Pleural Infiltrating T-Cell

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Iovance Biotherapeutics | UPMC Hillman Cancer Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Miltenyi Biotec

                            Germany arrow
                            CPhI India
                            Not Confirmed

                            Miltenyi Biotec

                            Germany arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SynKIR-110

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Verismo Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Verismo Therapeutics Partners Miltenyi Biotec for Clinical Program Support

                            Details : The collaboration aims to advance SynKIR-110 gene therapy targeting Mesothelin for solid tumors.

                            Product Name : SynKIR-110

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            September 25, 2025

                            Lead Product(s) : SynKIR-110

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Verismo Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Miltenyi Biotec

                            Germany arrow
                            CPhI India
                            Not Confirmed

                            Miltenyi Biotec

                            Germany arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TCRαβ+/CD45RA

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Recipient : Ruijin Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            T-Cell-Depleted Haplo Transplant + CAR-T & Memory T Cells in Acute Leukemia

                            Details : TCRαβ+/CD45RA is a Cell and Gene therapy drug candidate, which is currently being evaluated in clinical studies for the treatment of Leukemia.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            July 28, 2025

                            Lead Product(s) : TCRαβ+/CD45RA

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Recipient : Ruijin Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Miltenyi Biotec

                            Germany arrow
                            CPhI India
                            Not Confirmed

                            Miltenyi Biotec

                            Germany arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CBE-101

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Cell BioEngines

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Cell BioEngines Enters Agreement with Miltenyi Bioindustry to Manufacture Hematopoietic Cell Therapy Clinical ...

                            Details : Under the agreement, Miltenyi will develop and manufacture Cell BioEngines' expanded hematopoietic stem cell transplantation (HSCT) product, CBE-101, for clinical use in hematology-oncology.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            December 29, 2023

                            Lead Product(s) : CBE-101

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Cell BioEngines

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Miltenyi Biotec

                            Germany arrow
                            CPhI India
                            Not Confirmed

                            Miltenyi Biotec

                            Germany arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SY-001

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Syena

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Syena and Miltenyi Biotec Enter into Exclusive Licensing and GMP Manufacturing Agreement for PRAME TCR-NK Cell...

                            Details : Under the agreement, Syena will support the development of a GMP-compliant T-cell receptor (TCR) natural killer (NK) cell therapy, SY-001, targeting the tumor-associated neoantigen, PRAME.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            December 18, 2023

                            Lead Product(s) : SY-001

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Syena

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Miltenyi Biotec

                            Germany arrow
                            CPhI India
                            Not Confirmed

                            Miltenyi Biotec

                            Germany arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cyclophosphamide

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Hospital Israelita Albert Einstein

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase I Clinical Trial Using Genetically Engineered Autologous T Cells to Express Chimeric Antigen Receptor ...

                            Details : Cyclophosphamide is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Precursor Cell Lymphoblastic Leukemia-Lymphoma.

                            Product Name : Undisclosed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            January 31, 2023

                            Lead Product(s) : Cyclophosphamide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Hospital Israelita Albert Einstein

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Miltenyi Biotec

                            Germany arrow
                            CPhI India
                            Not Confirmed

                            Miltenyi Biotec

                            Germany arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CAR-T Cell

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : John Lister

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukem...

                            Details : CAR-T Cell is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Lymphoma, B-Cell.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            March 16, 2022

                            Lead Product(s) : CAR-T Cell

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : John Lister

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Miltenyi Biotec

                            Germany arrow
                            CPhI India
                            Not Confirmed

                            Miltenyi Biotec

                            Germany arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CAR20.19.22 Cell

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Medical College of Wisconsin

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies

                            Details : CAR20.19.22 Cell is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Lymphoma, B-Cell.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            October 26, 2021

                            Lead Product(s) : CAR20.19.22 Cell

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Medical College of Wisconsin

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Miltenyi Biotec

                            Germany arrow
                            CPhI India
                            Not Confirmed

                            Miltenyi Biotec

                            Germany arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ifn-Gamma Positive-Selected T-Cell

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I/ Phase II

                            Sponsor : Yae-Jean Kim

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Adoptive Transfer of pp65-specific T Cells for the Treatment of Refractory Cytomegalovirus (CMV) Infection

                            Details : Ifn-Gamma Positive-Selected T-Cell is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Cytomegalovirus Infections.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            January 27, 2015

                            Lead Product(s) : Ifn-Gamma Positive-Selected T-Cell

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Yae-Jean Kim

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Miltenyi Biotec

                            Germany arrow
                            CPhI India
                            Not Confirmed

                            Miltenyi Biotec

                            Germany arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CMV-Specific CTL

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : MD Anderson Cancer Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Autologous Cytomegalovirus (CMV)-Specific Cytotoxic T Cells for Cytomegalovirus (CMV) Reactivation

                            Details : CMV-Specific CTL is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Leukemia.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            August 06, 2014

                            Lead Product(s) : CMV-Specific CTL

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : MD Anderson Cancer Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth